['diabetic macular edema']
['intravitreous dexamethasone solution 4mg/ml - vol 0,01 ml', 'intravitreous dexamethasone solution 4mg/ml - vol 0,03 ml', 'intravitreous dexamethasone solution 4mg/ml - vol 0,05 ml']

        Inclusion Criteria:

          -  age > = 18 years;

          -  diagnosis of DM type 2;

          -  pseudophakic patients

          -  presence of clinically significant DME according to ETDRS guidelines;

          -  best correct visual acuity (BCVA) between 20/400 and 20/40;

          -  central macular thickness (CMT) >= 300 µm measured by spectral domain optical
             coherence tomography ( Spectralis® Heidelberg). If both eyes of the patient met the
             elegibility criteria, the eye with worse BCVA at baseline was designated as the study
             eye.

        Exclusion Criteria:

          -  any treatment of DME in the previous 4 months;

          -  pan retinal photocoagulation (PRP) in the previous 4 months or antecipated need of PRP
             for the next 6 months;

          -  any ophthalmologic surgery performed in the previous 4 months;

          -  history of pars plana vitrectomy;

          -  history of open-angle glaucoma or intraocular pressure elevation induced by
             corticosteroids that required anti-glaucomatous treatment or anti- hypertensive ocular
             treatment;

          -  intraocular pressure >= 21 mmHg;

          -  patients with characteristics that meet the inclusion criteria, but refused to sign
             the written general consent.
      